Testosterone phenylpropionate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Testosterone phenylpropionate is a steroid indicated for testosterone replacement therapy in sterilization, missing testicle, hypopituitarism, and osteoporosis.
- Generic Name
- Testosterone phenylpropionate
- DrugBank Accession Number
- DB16003
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 420.593
Monoisotopic: 420.266445019 - Chemical Formula
- C28H36O3
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBeclomethasone dipropionate The risk or severity of edema formation can be increased when Testosterone phenylpropionate is combined with Beclomethasone dipropionate. Betamethasone The risk or severity of edema formation can be increased when Testosterone phenylpropionate is combined with Betamethasone. Betamethasone phosphate The risk or severity of edema formation can be increased when Testosterone phenylpropionate is combined with Betamethasone phosphate. Budesonide The risk or severity of edema formation can be increased when Testosterone phenylpropionate is combined with Budesonide. Ciclesonide The risk or severity of edema formation can be increased when Testosterone phenylpropionate is combined with Ciclesonide. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image SUSTANON 250 INJECTION Testosterone phenylpropionate (60 mg/ml) + Testosterone decanoate (100 mg/ml) + Testosterone isocaproate (60 mg/ml) + Testosterone propionate (30 mg/ml) Injection Intramuscular DCH AURIGA SINGAPORE 1990-05-31 Not applicable Singapore TEST - COMP 250 Testosterone phenylpropionate (60 mg/mL) + Testosterone decanoate (100 mg/mL) + Testosterone isocaproate (60 mg/mL) + Testosterone propionate (30 mg/mL) Injection, solution บริษัท กรุงเทพ ฟาร์มา ดิสทริบิวชั่น จำกัด 2018-06-06 Not applicable Thailand
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8GN84GWX51
- CAS number
- 1255-49-8
- InChI Key
- HHSXYDOROIURIP-FEZCWRLCSA-N
- InChI
- InChI=1S/C28H36O3/c1-27-16-14-21(29)18-20(27)9-10-22-23-11-12-25(28(23,2)17-15-24(22)27)31-26(30)13-8-19-6-4-3-5-7-19/h3-7,18,22-25H,8-17H2,1-2H3/t22-,23-,24-,25-,27-,28-/m0/s1
- IUPAC Name
- (1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl 3-phenylpropanoate
- SMILES
- [H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
References
- General References
- FDA Thailand: Test - Comp 250 (Testosterone Decanoate, Testosterone Isocaproate, Testosterone Phenylpropionate, Testosterone Propionate) Injection [Link]
- External Links
- KEGG Compound
- C14667
- ChemSpider
- 14062
- 37855
- ChEBI
- 35002
- ChEMBL
- CHEMBL2356993
- ZINC
- ZINC000003881605
- Wikipedia
- Testosterone_phenylpropionate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular 100 mg/ml Injection, solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000283 mg/mL ALOGPS logP 4.61 ALOGPS logP 6.09 Chemaxon logS -6.2 ALOGPS pKa (Strongest Acidic) 18.52 Chemaxon pKa (Strongest Basic) -4.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 43.37 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 122.9 m3·mol-1 Chemaxon Polarizability 49.36 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-1060900000-8aee316468b104bc2e75 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0000900000-ff74935006ec7cbf12f0 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0fk9-0775900000-928794ac41bc89a131e9 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-2520900000-7273f3f1c0a68001159d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2902400000-44e6f9c4847e4143895d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00xr-3691200000-d6de9fc6c87232d36e64 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 222.0309513 predictedDarkChem Lite v0.1.0 [M-H]- 199.46483 predictedDeepCCS 1.0 (2019) [M+H]+ 222.9380513 predictedDarkChem Lite v0.1.0 [M+H]+ 201.36023 predictedDeepCCS 1.0 (2019) [M+Na]+ 222.1979513 predictedDarkChem Lite v0.1.0 [M+Na]+ 207.09157 predictedDeepCCS 1.0 (2019)
Drug created at December 10, 2020 21:04 / Updated at May 22, 2021 06:02